600056 中国医药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入26,099,730-12.41%38,824,43137,592,65036,234,41539,311,753
减:营业总成本25,216,784-12.09%37,501,89536,137,94034,480,96436,386,460
    其中:营业成本23,317,059-12.00%34,440,81432,845,78631,018,23932,512,228
               财务费用127,56289.74%112,038138,317221,691257,359
               资产减值损失1,150-74.02%(13,539)(280,660)(575,297)(682,774)
公允价值变动收益(1,109)-431.63%9851,922(2,135)656
投资收益5,003-82.02%(15,792)51,00143,65737,514
    其中:对联营企业和合营企业的投资收益35,149-46.51%77,04393,219113,90088,306
营业利润850,565-23.06%1,672,3341,199,698937,1351,939,187
利润总额842,784-24.02%1,640,5561,196,127940,1061,925,266
减:所得税费用221,866-31.84%398,435307,699225,830539,186
净利润620,918-20.77%1,242,120888,428714,2761,386,081
减:非控股权益173,770-8.33%194,081152,82767,21975,435
股东净利润447,148-24.74%1,048,039735,601647,0571,310,646

市场价值指针
每股收益 (元) *0.299-24.75%0.7010.4920.4331.227
每股派息 (元) *0.022--0.2100.1480.1820.368
每股净资产 (元) *7.7934.18%7.7287.230--9.364
审计意见 #--标准无保留意见标准无保留意见标准无保留意见--
回页顶
备注: *未调整数据
#只提供简体内容